QURE uniQure NV

uniQure N.V. (NASDAQ:QURE), a leader in human gene therapy, today announced that the Company has been added to the NASDAQ Biotechnology Index® (NBI) as part of NBI's annual selection of biotechnology and pharmaceutical companies listed on the NASDAQ Stock Market® that meet NBI's eligibility criteria. uniQure will be added to the NBI effective prior to market open on December 21, 2015.

The NASDAQ Biotechnology Index is a modified market capitalization weighted index that is designed to track the performance of a set of securities listed on The NASDAQ Stock Market® (NASDAQ®) that are classified as either biotechnology or pharmaceutical according to the Industry Classification Benchmark and is re-ranked annually in December.  Additional information on the eligibility criteria and further details about the index are available here: https://indexes.nasdaqomx.com/docs/methodology_NBI.pdf

About uniQure

uniQure is delivering on the promise of gene therapy – single treatments with potentially curative results. We are leveraging our modular and validated technology platform to rapidly advance a pipeline of proprietary and partnered gene therapies to treat patients with CNS, liver/metabolic and cardiovascular diseases. www.uniQure.com

CONTACT: uniQure:                                      
         Aicha Diba                                     
         Investor Relations                             
         Direct : +31 20 240 6100                       
         Main: +31 20 566 7394                  
         a.diba@uniQure.com                             

         Media inquiries:
         Gretchen Schweitzer 
         MacDougall Biomedical Communications
         Direct: +49 172 861 8540
         Main: +49 89 2424 3494 or +1 781 235 3060
         gschweitzer@macbiocom.com